Inhibition of the renin-angiotensin system: is more better?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19092813.
- Also identified by DOI 10.1038/ki.2008.556.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibitors of the renin-angiotensin-aldosterone system (RAS) exert beneficial effects in diabetic nephropathy, but the possibility of regression of existing renal lesions remains to be investigated. Teles et al. tested the effects of the RAS inhibitor losartan in rats starting 10 months after induction of diabetes, when glomerular lesions were already present. They linked the reductions of proteinuria with regression of mesangial expansion. More advanced lesions were not affected. There were no dose-response renal effects of losartan.
Medical subject headings
- Diabetic Nephropathies
- Renin-Angiotensin System